(ATOM) Atomera - Overview
Stock: Silicon Film, Transistor Enhancement, CMOS Optimization
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 125% |
| Relative Tail Risk | -14.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.71 |
| Alpha | -103.82 |
| Character TTM | |
|---|---|
| Beta | 2.380 |
| Beta Downside | 1.648 |
| Drawdowns 3y | |
|---|---|
| Max DD | 87.98% |
| CAGR/Max DD | -0.35 |
Description: ATOM Atomera January 20, 2026
Atomera Inc. (NASDAQ:ATOM) develops, licenses, and commercializes proprietary semiconductor materials, most notably its Mears Silicon Technology (MST) – a thin-film silicon layer that enhances transistor channel performance in CMOS devices. The company serves a broad customer base that includes foundries, integrated device manufacturers, fabless designers, OEMs, and EDA firms. Originally incorporated as Mears Technologies in 2001, it rebranded to Atomera in January 2016 and is headquartered in Los Gatos, California.
Recent filings show Atomera generated roughly $5.5 million in revenue for the latest quarter, with cash and cash equivalents of about $45 million, giving it a runway of over a year at current burn rates. The firm’s growth prospects are tied to two sector drivers: (1) the industry-wide push toward sub-5 nm nodes, which raises demand for channel-enhancement materials, and (2) the ongoing fab-capacity expansion in Asia-Pacific, where its primary foundry customers are scaling production. A notable partnership with a leading global foundry (announced in Q3 2023) aims to qualify MST for 3 nm and beyond, potentially unlocking a multi-year licensing pipeline.
For a deeper, data-driven look at Atomera’s valuation dynamics, you might find ValueRay’s analyst framework useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -20.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.67 > 0.02 and ΔFCF/TA -1.93 > 1.0 |
| NWC/Revenue: 47.7k% < 20% (prev 2176 %; Δ 45.5k% < -1%) |
| CFO/TA -0.67 > 3% & CFO -14.7m > Net Income -20.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.1m) vs 12m ago 13.58% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.18% > 50% (prev 3.29%; Δ -3.11% > 0%) |
| Interest Coverage Ratio: -267.5 > 6 (EBITDA TTM -19.3m / Interest Expense TTM 76.0k) |
Altman Z'' -15.00
| A: 0.83 (Total Current Assets 21.0m - Total Current Liabilities 2.91m) / Total Assets 21.9m |
| B: -10.81 (Retained Earnings -237.3m / Total Assets 21.9m) |
| C: -0.97 (EBIT TTM -20.3m / Avg Total Assets 21.0m) |
| D: -81.50 (Book Value of Equity -237.2m / Total Liabilities 2.91m) |
| Altman-Z'' Score: -121.9 = D |
Beneish M 1.00
| DSRI: 56.48 (Receivables 201.0k/62.0k, Revenue 38.0k/662.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.12 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 0.06 (Revenue 38.0k / 662.0k) |
| TATA: -0.26 (NI -20.4m - CFO -14.7m) / TA 21.9m) |
| Beneish M-Score: 41.17 (Cap -4..+1) = D |
What is the price of ATOM shares?
Over the past week, the price has changed by -12.29%, over one month by +12.23%, over three months by -0.39% and over the past year by -73.94%.
Is ATOM a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ATOM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5 | 94.6% |
| Analysts Target Price | 5 | 94.6% |
| ValueRay Target Price | 1.7 | -33.5% |
ATOM Fundamental Data Overview February 05, 2026
P/B = 4.4284
Revenue TTM = 38.0k USD
EBIT TTM = -20.3m USD
EBITDA TTM = -19.3m USD
Long Term Debt = 794.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 794.0k USD (from shortTermDebt, last quarter)
Debt = 794.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -19.5m USD (from netDebt column, last quarter)
Enterprise Value = 64.7m USD (84.3m + Debt 794.0k - CCE 20.3m)
Interest Coverage Ratio = -267.5 (Ebit TTM -20.3m / Interest Expense TTM 76.0k)
EV/FCF = -4.40x (Enterprise Value 64.7m / FCF TTM -14.7m)
FCF Yield = -22.72% (FCF TTM -14.7m / Enterprise Value 64.7m)
FCF Margin = -38.7k% (FCF TTM -14.7m / Revenue TTM 38.0k)
Net Margin = -53.7k% (Net Income TTM -20.4m / Revenue TTM 38.0k)
Gross Margin = unknown ((Revenue TTM 38.0k - Cost of Revenue TTM 529.0k) / Revenue TTM)
Tobins Q-Ratio = 2.95 (Enterprise Value 64.7m / Total Assets 21.9m)
Interest Expense / Debt = 1.51% (Interest Expense 12.0k / Debt 794.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -16.1m (EBIT -20.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.23 (Total Current Assets 21.0m / Total Current Liabilities 2.91m)
Debt / Equity = 0.04 (Debt 794.0k / totalStockholderEquity, last quarter 19.0m)
Debt / EBITDA = 1.01 (negative EBITDA) (Net Debt -19.5m / EBITDA -19.3m)
Debt / FCF = 1.33 (negative FCF - burning cash) (Net Debt -19.5m / FCF TTM -14.7m)
Total Stockholder Equity = 22.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -96.98% (Net Income -20.4m / Total Assets 21.9m)
RoE = -92.04% (Net Income TTM -20.4m / Total Stockholder Equity 22.2m)
RoCE = -88.53% (EBIT -20.3m / Capital Employed (Equity 22.2m + L.T.Debt 794.0k))
RoIC = -72.44% (negative operating profit) (NOPAT -16.1m / Invested Capital 22.2m)
WACC = 14.56% (E(84.3m)/V(85.1m) * Re(14.69%) + D(794.0k)/V(85.1m) * Rd(1.51%) * (1-Tc(0.21)))
Discount Rate = 14.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.69%
Fair Price DCF = unknown (Cash Flow -14.7m)
EPS Correlation: 29.71 | EPS CAGR: 41.53% | SUE: 4.0 | # QB: 1
Revenue Correlation: -15.21 | Revenue CAGR: 1427 % | SUE: -1.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.53 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+3.6% | Growth Revenue=+300.0%